Abstract:Background: The predictive capability of the current immunotherapy biomarkers is still unsatisfying. Although alterations in DNA damage response and repair (DDR) genes were shown to be a potential immunotherapy biomarker in certain cancer types, no reliable DDR gene panel was available and whether DDR gene alterations are associated with outcomes to immune checkpoint blockades (ICBs) across cancer types and drug classes is unknown.Methods: In this study, we used the publicly available genomic data from the training set of 1630 patients with eleven different types of cancer treated with ICBs in Memorial Sloan-Kettering Cancer Center (MSKCC) to analyze for the mutational status across a panel of 43 DDR genes covered in all three versions of MSK-IMPACT. Then, we developed a ten-DDR-gene score (DDRScore) by use of LASSO Cox regression followed by stepwise regression analysis through bidirectional elimination, based on association between mutational status of DDR genes and overall survival after ICB treatment. The predictive value of DDRScore for immunotherapy benefit was validated in six previously published independent validation cohorts (three melanoma cohorts and three non-small lung cancer cohorts), among which, 844 patients were assessed for progression-free survival (PFS), 633 were assessed for overall survival (OS), and 659 were evaluated for objective response rate (ORR). We used Cox regression to test the association between DDRScore and clinical outcomes to ICBs and tumor mutational burden (TMB) for comparison. The χ2 test was used to test the difference of response rate between the DDRScore-high (DDRScore-H) and non-DDRScore-H groups. The main outcomes were OS and PFS; the secondary outcome was ORR.Findings: In the training cohort, higher DDRScore (cut-points stratified by cancer types) was associated with better OS (hazard ratio [HR] 0.54 [0.43-0.67]). Additionally, an association between higher DDRScore and improved OS was found in most cancer histologies and all drug classes. The HRs for tissue TMB (tTMB) (≥10 muts/Mb) and tTMB (top 20% within each histology) were 0.57 (0.48-0.67) and 0.64 (0.53-0.77), respectively, for OS in the training cohort as a whole, and tTMB associated with these two cut-points failed to reach statistical significance in predicting OS benefit from ICB combinations. In the validation cohorts, pooled analysis demonstrated that DDRScore using the same cut-points of training cohort was associated with PFS (0.69 [0.57-0.83]), OS (0.67 [0.52-0.85]) and ORR (p=0.01). Although higher tTMB with a fixed cut-off (tTMB ≥10 muts/Mb or blood TMB ≥16 muts/Mb) or stratified by cancer types (top 20% within histologies) correlated with better PFS (HRs were 0.78 [0.66-0.92] and 0.68 [0.56-0.83]) in the pooled analysis of validated cohorts, they performed worse predicting OS benefit (HRs were 0.87 [0.71-1.08] and 0.86 [0.68-1.10]). Finally, HR for combination of DDRScore and TMB with a fixed cut-off for OS in the training cohort was 0.40 (0.30-0.53), and HRs for the combination biomarker in the validation cohorts were 0.61 (0.48-0.78) and 0.61 (0.45-0.83) for PFS and OS, respectively.Interpretation: DDRScore seemed to a reliable and feasible approach to guide ICB treatment. The predictive value of DDRScore was stable across cancer types and drug classes, and outperformed that of TMB in most situations. The combination of DDRScore and TMB can provide more accurate prediction of immunotherapy benefit.Funding Information: This study was supported by National Natural Science Foundation of China (No. 81672738) and Guangzhou Science and Technology Foundation of China (No.201704020095).Declaration of Interests: The authors declare no competing interests.

Germline DNA damage response gene mutations as predictive biomarkers of immune checkpoint inhibitor efficacy

Alterations in DNA Damage Response and Repair Genes As Potential Biomarkers for Immune Checkpoint Blockade in Gastrointestinal Cancer

DNA Damage Repair Gene Mutations Are Indicative of a Favorable Prognosis in Colorectal Cancer Treated With Immune Checkpoint Inhibitors

Impact of DNA Damage Response and Repair (DDR) Gene Mutations on Efficacy of PD-(L)1 Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Pan-Cancer Prediction of Immunotherapy Benefit Using DNA Damage Response and Repair Gene Signature: A Model Development and Validation Study

Are DNA Repair Gene Alterations Associated With the Response to Platinum-Based Regimen and Immune Checkpoint Inhibitors in Patients With Solid Tumors?

DNA damage response-related immune activation signature predicts the response to immune checkpoint inhibitors: from gastrointestinal cancer analysis to pan-cancer validation

Role of DNA Repair Defects in Predicting Immunotherapy Response

Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications

PATH01.03 Mutational Landscape and Prognosis Prediction for Immune Checkpoint Blockades of DNA Damage Response Pathways in Non-Small Cell Lung Cancer

DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma

The Role of DNA Damage Repair (DDR) System in Response to Immune Checkpoint Inhibitor (ICI) Therapy

Epigenetic-related gene mutations serve as potential biomarkers for immune checkpoint inhibitors in microsatellite-stable colorectal cancer

Comprehensive analysis of DNA damage repair deficiency in 10,284 pan-cancer study

Prevalence of Prkdc Mutations and Association with Response to Immune Checkpoint Inhibitors in Solid Tumors.

Novel epigenetic signature of DNA damage response genes for prognostication and immunophenotype of non-G-CIMP glioblastomas

Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.

Clinical and Genomic Characteristics Between DDR Germline and Somatic Mutations in Pan-Cancer

Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study

Exploration of Germline Correlates and Risk of Immune-Related Adverse Events in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors

Mutational landscape of DNA damage response deficiency-related genes and its association with immune biomarkers in esophageal squamous cell carcinoma.